Work

Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.4566

Authors: Rosa Nadal, Asim Amin, Daniel M. Geynisman, Martin Henner Voss, Matthew Weinstock, Jaime Doyle, Zhe Zhang, Antonio Viudez, Elizabeth R. Plimack, David F. McDermott, Robert Motzer, Brian I. Rini, Hans J. Hammers

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Levine Cancer Institute, Fox Chase Cancer Center, Memorial Sloan Kettering Cancer Center, Beth Israel Deaconess Medical Center, Temple University Health System, Cleveland Clinic

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2528048907

Cites:

Cited by: 4

Related to: 10